{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:05:33Z","timestamp":1791475533312,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T00:00:00Z","timestamp":1629590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T00:00:00Z","timestamp":1629590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100008001","name":"Universit\u00e4t zu K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008001","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40262-021-01063-5","type":"journal-article","created":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T23:15:15Z","timestamp":1629587715000},"page":"1495-1508","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol"],"prefix":"10.1007","volume":"60","author":[{"given":"Muhammad","family":"Bilal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lobna","family":"El Tabei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren","family":"B\u00fcsker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Fuhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8925-7782","authenticated-orcid":false,"given":"Max","family":"Taubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,22]]},"reference":[{"key":"1063_CR1","doi-asserted-by":"publisher","first-page":"S538","DOI":"10.1093\/cid\/ciz826","volume":"69","author":"T Sato","year":"2019","unstructured":"Sato T, Yamawaki K. Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin Infect Dis. 2019;69:S538\u201343.","journal-title":"Clin Infect Dis"},{"key":"1063_CR2","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.ejmech.2018.06.014","volume":"155","author":"T Aoki","year":"2018","unstructured":"Aoki T, Yoshizawa H, Yamawaki K, Yokoo K, Sato J, Hisakawa S, et al. Cefiderocol (S-649266), a new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: structure activity relationship. Eur J Med Chem. 2018;155:847\u201368.","journal-title":"Eur J Med Chem"},{"key":"1063_CR3","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1177\/1060028020929988","volume":"54","author":"RM El-Lababidi","year":"2020","unstructured":"El-Lababidi RM, Rizk JG. Cefiderocol: a siderophore cephalosporin. Ann Pharmacother. 2020;54:1215\u201331.","journal-title":"Ann Pharmacother"},{"key":"1063_CR4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","volume":"21","author":"M Bassetti","year":"2021","unstructured":"Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21:226\u201340.","journal-title":"Lancet Infect Dis"},{"key":"1063_CR5","unstructured":"Shionogi & Co. Ltd. Structured product label of Fetroja. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209445s002lbl.pdf. Accessed 31 Jul 2021"},{"key":"1063_CR6","unstructured":"European Medicines Agency. EMEA\/H\/C\/004829: summary of product characteristics of Fetcroja. 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fetcroja. Accessed 31 Jul 2021"},{"key":"1063_CR7","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/phar.2476","volume":"40","author":"JC Abdul-Mutakabbir","year":"2020","unstructured":"Abdul-Mutakabbir JC, Alosaimy S, Morrisette T, Kebriaei R, Rybak MJ. Cefiderocol: a novel siderophore cephalosporin against multidrug-resistant Gram-negative pathogens. Pharmacotherapy. 2020;40:1228\u201347.","journal-title":"Pharmacotherapy"},{"key":"1063_CR8","doi-asserted-by":"publisher","first-page":"26723","DOI":"10.1074\/jbc.270.45.26723","volume":"270","author":"JB Neilands","year":"1995","unstructured":"Neilands JB. Siderophores: structure and function of microbial iron transport compounds. J Biol Chem. 1995;270:26723\u20136.","journal-title":"J Biol Chem"},{"key":"1063_CR9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1039\/b906679a","volume":"27","author":"RC Hider","year":"2010","unstructured":"Hider RC, Kong X. Chemistry and biology of siderophores. Nat Prod Rep. 2010;27:637\u201357.","journal-title":"Nat Prod Rep"},{"key":"1063_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10534-008-9199-7","volume":"22","author":"V Braun","year":"2009","unstructured":"Braun V, Pramanik A, Gwinner T, K\u00f6berle M, Bohn E. Sideromycins: tools and antibiotics. Biometals. 2009;22:3\u201313.","journal-title":"Biometals"},{"key":"1063_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/7355_2017_19","volume":"26","author":"TA Wencewicz","year":"2018","unstructured":"Wencewicz TA, Miller MJ. Sideromycins as pathogen-targeted antibiotics. Top Med Chem. 2017;26:151\u201383. https:\/\/doi.org\/10.1007\/7355_2017_19","journal-title":"Top Med Chem"},{"key":"1063_CR12","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1007\/s10096-017-3063-z","volume":"36","author":"J Dobias","year":"2017","unstructured":"Dobias J, D\u00e9nervaud-Tendon V, Poirel L, Nordmann P. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Eur J Clin Microbiol Infect Dis. 2017;36:2319\u201327.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1063_CR13","doi-asserted-by":"crossref","unstructured":"Hackel M, Tsuji M, Echols R, Sahm D. In vitro antibacterial activity of cefiderocol (S-649266) against Gram-negative clinical strains collected in North America and Europe (SIDERO-WT-2014 study). Poster Present IDWeek. 2016; pp. 26\u201330. www.ihma.com\/app\/uploads\/1828.pdf","DOI":"10.1093\/ofid\/ofw172.1376"},{"key":"1063_CR14","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1128\/AAC.01695-15","volume":"60","author":"N Kohira","year":"2016","unstructured":"Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, et al. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother. 2016;60:729\u201334.","journal-title":"Antimicrob Agents Chemother"},{"key":"1063_CR15","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ijantimicag.2018.11.007","volume":"53","author":"JA Karlowsky","year":"2019","unstructured":"Karlowsky JA, Hackel MA, Tsuji M, Yamano Y, Echols R, Sahm DF. In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015\u20132016: SIDERO-WT-2015. Int J Antimicrob Agents. 2019;53:456\u201366.","journal-title":"Int J Antimicrob Agents"},{"key":"1063_CR16","doi-asserted-by":"publisher","unstructured":"Warner NC, Bartelt LA, Lachiewicz AM, Tompkins KM, Miller MB, Alby K, et al. Cefiderocol for the treatment of adult and pediatric patients with cystic fibrosis and Achromobacter xylosoxidans infections. Clin Infect Dis. 2020;ciaa1847. https:\/\/doi.org\/10.1093\/cid\/ciaa1847","DOI":"10.1093\/cid\/ciaa1847"},{"key":"1063_CR17","doi-asserted-by":"publisher","first-page":"e02163","DOI":"10.1128\/AAC.02163-17","volume":"62","author":"Y Saisho","year":"2018","unstructured":"Saisho Y, Katsube T, White S, Fukase H, Shimada J. Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for Gram-negative bacteria, in healthy subjects. Antimicrob Agents Chemother. 2018;62:e02163-e2217.","journal-title":"Antimicrob Agents Chemother"},{"key":"1063_CR18","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1002\/jcph.1386","volume":"59","author":"S Miyazaki","year":"2019","unstructured":"Miyazaki S, Katsube T, Shen H, Tomek C, Narukawa Y. Metabolism, excretion, and pharmacokinetics of [14C]-cefiderocol (S-649266), a siderophore cephalosporin, in healthy subjects following intravenous administration. J Clin Pharmacol. 2019;59:958\u201367.","journal-title":"J Clin Pharmacol"},{"key":"1063_CR19","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1093\/jac\/dkz123","volume":"74","author":"T Katsube","year":"2019","unstructured":"Katsube T, Saisho Y, Shimada J, Furuie H. Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects. J Antimicrob Chemother. 2019;74:1971\u20134.","journal-title":"J Antimicrob Chemother"},{"key":"1063_CR20","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s40261-020-00955-x","volume":"40","author":"YR Lee","year":"2020","unstructured":"Lee YR, Yeo S. Cefiderocol, a new siderophore cephalosporin for the treatment of complicated urinary tract infections caused by multidrug-resistant pathogens: preclinical and clinical pharmacokinetics, pharmacodynamics, efficacy and safety. Clin Drug Investig. 2020;40:901\u201313.","journal-title":"Clin Drug Investig"},{"key":"1063_CR21","first-page":"1","volume":"63","author":"R Nakamura","year":"2019","unstructured":"Nakamura R, Ito-Horiyama T, Takemura M, Toba S, Matsumoto S, Ikehara T, et al. In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models. Antimicrob Agents Chemother. 2019;63:1\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"1063_CR22","doi-asserted-by":"publisher","first-page":"e01391","DOI":"10.1128\/AAC.01391-17","volume":"62","author":"N Kawaguchi","year":"2018","unstructured":"Kawaguchi N, Katsube T, Echols R, Wajima T. Population pharmacokinetic analysis of cefiderocol, a parenteral siderophore cephalosporin, in healthy subjects, subjects with various degrees of renal function, and patients with complicated urinary tract infection or acute uncomplicated pyelonephritis. Antimicrob Agents Chemother. 2018;62:e01391-e1417.","journal-title":"Antimicrob Agents Chemother"},{"key":"1063_CR23","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/jcph.841","volume":"57","author":"T Katsube","year":"2017","unstructured":"Katsube T, Echols R, Ferreira JCA, Krenz HK, Berg JK, Galloway C. Cefiderocol, a siderophore cephalosporin for Gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment. J Clin Pharmacol. 2017;57:584\u201391.","journal-title":"J Clin Pharmacol"},{"key":"1063_CR24","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3390\/antibiotics10060649","volume":"10","author":"C K\u00f6nig","year":"2021","unstructured":"K\u00f6nig C, Both A, Rohde H, Kluge S, Frey OR, R\u00f6hr AC, et al. Cefiderocol in critically ill patients with multi-drug resistant pathogens: real-life data on pharmacokinetics and microbiological surveillance. Antibiotics. 2021;10:649.","journal-title":"Antibiotics"},{"key":"1063_CR25","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00228-018-2458-9","volume":"74","author":"T Katsube","year":"2018","unstructured":"Katsube T, Miyazaki S, Narukawa Y, Hernandez-Illas M, Wajima T. Drug\u2013drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters. Eur J Clin Pharmacol. 2018;74:931\u20138.","journal-title":"Eur J Clin Pharmacol"},{"key":"1063_CR26","doi-asserted-by":"publisher","first-page":"e01381","DOI":"10.1128\/AAC.01381-16","volume":"61","author":"T Katsube","year":"2017","unstructured":"Katsube T, Wajima T, Ishibashi T, Ferreira JCA, Echols R. Pharmacokinetic\/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function. Antimicrob Agents Chemother. 2017;61:e01381-e1416.","journal-title":"Antimicrob Agents Chemother"},{"key":"1063_CR27","doi-asserted-by":"publisher","first-page":"e01437","DOI":"10.1128\/AAC.01437-20","volume":"65","author":"N Kawaguchi","year":"2021","unstructured":"Kawaguchi N, Katsube T, Echols R, Wajima T. Population pharmacokinetic and pharmacokinetic\/pharmacodynamic analyses of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia, bloodstream infection\/sepsis, or complicated urinary tract infection. Antimicrob Agents Chemother. 2021;65:e01437-e1520.","journal-title":"Antimicrob Agents Chemother"},{"key":"1063_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","volume":"21","author":"RG Wunderink","year":"2021","unstructured":"Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021;21:213\u201325.","journal-title":"Lancet Infect Dis"},{"key":"1063_CR29","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","volume":"18","author":"S Portsmouth","year":"2018","unstructured":"Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18:1319\u201328.","journal-title":"Lancet Infect Dis"},{"key":"1063_CR30","doi-asserted-by":"publisher","first-page":"e00700","DOI":"10.1128\/AAC.00700-17","volume":"61","author":"S Matsumoto","year":"2017","unstructured":"Matsumoto S, Singley CM, Hoover J, Nakamura R, Echols R, Rittenhouse S, et al. Efficacy of cefiderocol against carbapenem-resistant gram-negative bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics. Antimicrob Agents Chemother. 2017;61:e00700-e717.","journal-title":"Antimicrob Agents Chemother"},{"key":"1063_CR31","first-page":"e01022","volume":"61","author":"ML Monogue","year":"2017","unstructured":"Monogue ML, Tsuji M, Yamano Y, Echols R, Nicolaua DP. Efficacy of humanized exposures of cefiderocol (S-649266) against a diverse population of Gram-negative bacteria in a murine thigh infection model. Antimicrob Agents Chemother. 2017;61:e01022-e1117.","journal-title":"Antimicrob Agents Chemother"},{"key":"1063_CR32","doi-asserted-by":"publisher","first-page":"e01040","DOI":"10.1128\/AAC.01040-18","volume":"63","author":"SM Stainton","year":"2019","unstructured":"Stainton SM, Monogue ML, Tsuji M, Yamano Y, Echols R, Nicolau DP. Efficacy of humanized cefiderocol exposures over 72 hours against a diverse group of Gram-negative isolates in the neutropenic murine thigh infection model. Antimicrob Agents Chemother. 2019;63:e01040-e1118.","journal-title":"Antimicrob Agents Chemother"},{"key":"1063_CR33","doi-asserted-by":"publisher","first-page":"S472","DOI":"10.1093\/ofid\/ofx163.1208","volume":"4","author":"S Matsumoto","year":"2017","unstructured":"Matsumoto S, Kanazawa S, Nakamura R, Tsuji M, Sato T, Yamano Y. In vivo efficacy of cefiderocol against carbapenem-resistant Gram-negative bacilli in murine urinary tract infection models. Open Forum Infect Dis. 2017;4:S472.","journal-title":"Open Forum Infect Dis"},{"key":"1063_CR34","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1159\/000487441","volume":"101","author":"IM Ghazi","year":"2018","unstructured":"Ghazi IM, Monogue ML, Tsuji M, Nicolau DP. Humanized exposures of cefiderocol, a siderophore cephalosporin, display sustained in vivo activity against siderophore-resistant Pseudomonas aeruginosa. Pharmacology. 2018;101:278\u201384.","journal-title":"Pharmacology"},{"key":"1063_CR35","doi-asserted-by":"publisher","first-page":"7396","DOI":"10.1128\/AAC.01405-16","volume":"60","author":"A Ito","year":"2016","unstructured":"Ito A, Nishikawa T, Matsumoto S, Yoshizawa H, Sato T, Nakamura R, et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60:7396\u2013401.","journal-title":"Antimicrob Agents Chemother"},{"key":"1063_CR36","first-page":"e01961","volume":"64","author":"JM Kidd","year":"2020","unstructured":"Kidd JM, Abdelraouf K, Nicolau DP. Development of neutropenic murine models of iron overload and depletion to study the efficacy of siderophore-antibiotic conjugates. Antimicrob Agents Chemother. 2020;64:e01961-e2019.","journal-title":"Antimicrob Agents Chemother"},{"key":"1063_CR37","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","volume":"58","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al. DALI: defining antibiotic levels in intensive care unit patients: are current \u00df-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58:1072\u201383.","journal-title":"Clin Infect Dis"},{"key":"1063_CR38","unstructured":"Federal Drug Administration. FDA briefing document for the AMDAC. 2019. https:\/\/www.fda.gov\/media\/131703\/download. Accessed 31 Jul 2021"},{"key":"1063_CR39","unstructured":"Shionogi Inc. Cefiderocol advisory committee briefing document. 2019. https:\/\/www.fda.gov\/media\/131705\/download. Accessed 31 Jul 2021"},{"key":"1063_CR40","first-page":"S330","volume":"6","author":"T Katsube","year":"2019","unstructured":"Katsube T, Echols R, Wajima T. 739. Prediction of cefiderocol pharmacokinetics and probability of target attainment in pediatric subjects for proposing dose regimens. Open Forum Infect Dis. 2019;6:S330\u20131.","journal-title":"Open Forum Infect Dis"},{"key":"1063_CR41","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1002\/ppul.24945","volume":"55","author":"AB Gainey","year":"2020","unstructured":"Gainey AB, Burch AK, Brownstein MJ, Brown DE, Fackler J, Horne B, et al. Combining bacteriophages with cefiderocol and meropenem\/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient. Pediatr Pulmonol. 2020;55:2990\u20134.","journal-title":"Pediatr Pulmonol"},{"key":"1063_CR42","unstructured":"Center for Drug Evaluation and Research (Food and Drug Administration). Approval package for Fetroja. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/209445Orig1s002.pdf. Accessed 31 Jul 2021"},{"key":"1063_CR43","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/jac\/dkab015","volume":"76","author":"KA Parsels","year":"2021","unstructured":"Parsels KA, Mastro KA, Steele JM, Thomas SJ, Kufel WD. Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections. J Antimicrob Chemother. 2021;76:1379\u201391.","journal-title":"J Antimicrob Chemother"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01063-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-021-01063-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01063-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T21:09:45Z","timestamp":1637788185000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-021-01063-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,22]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1063"],"URL":"https:\/\/doi.org\/10.1007\/s40262-021-01063-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,22]]},"assertion":[{"value":"26 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. This work was based on internal funding of the Department I of Pharmacology, University of Cologne, Cologne, Germany.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Muhammad Bilal, Lobna El Tabei, S\u00f6ren B\u00fcsker, Christian Krauss, and Uwe Fuhr declare no conflict of interest. Max Taubert is an employee of Novartis AG.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors screened articles and abstracts for inclusion, discussed results and conclusions, and wrote the  manuscript. MT and UF supervised the review process.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}}]}}